Sumitomo Mitsui DS Asset Management Company Ltd Acquires 143 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Sumitomo Mitsui DS Asset Management Company Ltd raised its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 1.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,638 shares of the medical instruments supplier’s stock after purchasing an additional 143 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in West Pharmaceutical Services were worth $2,293,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Fidelis Capital Partners LLC purchased a new position in West Pharmaceutical Services in the 1st quarter worth about $27,000. Crewe Advisors LLC raised its stake in shares of West Pharmaceutical Services by 322.7% during the second quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier’s stock valued at $31,000 after acquiring an additional 71 shares in the last quarter. Northwest Investment Counselors LLC purchased a new stake in shares of West Pharmaceutical Services in the first quarter valued at approximately $40,000. ORG Partners LLC grew its stake in West Pharmaceutical Services by 820.0% in the first quarter. ORG Partners LLC now owns 138 shares of the medical instruments supplier’s stock worth $55,000 after purchasing an additional 123 shares in the last quarter. Finally, Quest Partners LLC increased its holdings in West Pharmaceutical Services by 5,633.3% during the 2nd quarter. Quest Partners LLC now owns 172 shares of the medical instruments supplier’s stock worth $57,000 after purchasing an additional 169 shares during the period. 93.90% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at West Pharmaceutical Services

In related news, VP Charles Witherspoon sold 1,029 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $300.00, for a total value of $308,700.00. Following the completion of the transaction, the vice president now owns 1,478 shares of the company’s stock, valued at $443,400. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Trading Down 2.1 %

Shares of NYSE WST opened at $287.25 on Tuesday. West Pharmaceutical Services, Inc. has a twelve month low of $265.00 and a twelve month high of $413.70. The company has a quick ratio of 1.68, a current ratio of 2.34 and a debt-to-equity ratio of 0.03. The business has a fifty day simple moving average of $299.96 and a two-hundred day simple moving average of $324.52. The firm has a market cap of $20.84 billion, a PE ratio of 40.86, a price-to-earnings-growth ratio of 10.46 and a beta of 1.01.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings data on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share for the quarter, missing the consensus estimate of $1.74 by ($0.22). West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. The firm had revenue of $702.10 million during the quarter, compared to the consensus estimate of $729.36 million. During the same quarter in the previous year, the firm earned $2.11 earnings per share. The business’s revenue was down 6.9% compared to the same quarter last year. Analysts expect that West Pharmaceutical Services, Inc. will post 6.42 earnings per share for the current fiscal year.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.